Allergan’s most recent trend suggests a bearish bias. One trading opportunity on Allergan is a Bear Call Spread using a strike $180.00 short call and a strike $190.00 long call offers a potential 19.19% return on risk over the next 29 calendar days. Maximum profit would be generated if the Bear Call Spread were to expire worthless, which would occur if the stock were below $180.00 by expiration. The full premium credit of $1.61 would be kept by the premium seller. The risk of $8.39 would be incurred if the stock rose above the $190.00 long call strike price.
The 5-day moving average is moving down which suggests that the short-term momentum for Allergan is bearish and the probability of a decline in share price is higher if the stock starts trending.
The 20-day moving average is moving down which suggests that the medium-term momentum for Allergan is bearish.
The RSI indicator is at 38.39 level which suggests that the stock is neither overbought nor oversold at this time.
To learn how to execute such a strategy while accounting for risk and reward in the context of smart portfolio management, and see how to trade live with a successful professional trader, view more here
LATEST NEWS for Allergan
Norwegian Cruise Line Holdings: Cramer’s Top Takeaways
Wed, 15 Nov 2017 01:15:00 +0000
Frank Del Rio, president and CEO of Norwegian Cruise Line Holdings Ltd., tells Jim Cramer why cruises appeal to younger travelers.
Allergan’s Vraylar Gets FDA Nod for Maintenance Therapy
Tue, 14 Nov 2017 21:16:09 +0000
Allergan’s (AGN) schizophrenia capsule, Vraylar, secures an FDA approval for its label expansion as a maintenance treatment option in the market.
Here’s What’s Behind Synergy Pharmaceuticals’ 15.6% Drop Today
Tue, 14 Nov 2017 19:54:00 +0000
The company’s making inroads with its first commercial-stage drug, but expenses could present big headwinds.
Overactive Bladder Causes Significant Burden, Regardless of Age Amongst Adults
Tue, 14 Nov 2017 13:00:00 +0000
DUBLIN and CHARLESTON, S.C., Nov. 14, 2017 /PRNewswire/ — Allergan, Inc. (AGN), in partnership with the National Association For Continence (NAFC), today announced the results of a new survey that revealed the impact of overactive bladder (OAB) and related symptoms on those living with the condition, as well as the extremes to which people will go to cope with or hide their symptoms. “People can start experiencing symptoms of OAB at an early age, learning to settle for a lifetime of silently struggling with an uncomfortable condition,” says Steven Gregg, PhD, Executive Director of the NAFC. The survey found that 86 percent of respondents experience OAB symptoms multiple times a day.
Allergan to sell a quarter of its Teva stake in first quarter 2018
Mon, 13 Nov 2017 20:37:18 +0000
Allergan Plc said on Monday it will sell just under a quarter of its roughly 10 percent stake in Israel’s Teva Pharmaceutical Industries during the first quarter of 2018, as it starts to unwind its position in the struggling generic drugmaker. Botox maker Allergan said in a filing with the Securities and Exchange Commission that it will sell 25 million shares to a JP Morgan Chase and Co unit – acting as a dealer for the shares – sometime next quarter. The JP Morgan unit will pay a price based on the average trading price over a yet-to-be determined period before the sale.
Follow Us on Facebook